n-acetylglucosamine
Small moleculeexperimental
N-Acetylglucosamine (GlcNAc) is an amide derivative of the monosaccharide glucose. It is a secondary amide between glucosamine and acetic acid. It is significant in several biological systems. — Wikipedia
Clinical trial activity
7 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Apr 1, 2013 (NCT01893606)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O- Mol. weight
- 221.21 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaN-Acetylglucosamine ↗
- ChEMBLCHEMBL447878 ↗
Also known as
- 2-acetamido-2-deoxy-d-glucose
- 2-acetamido-2-deoxy-d-glucose
- acetylglucosamine
- aldehydo-n-acetyl-d-glucosamine
- aldehydo-n-acetyl-d-glucosamine
- d-glcnac
- d-glcnac
- n-acetylchitosamine
- n-acetylchitosamine
- n-acetyl-d-glucosamine
- n-acetyl-d-glucosamine
- n-acetyl-d-glucosamine
- n-acetyl-d-glucosamine
- n-acetyl-d-glucosamine
- n-acetyl-d-glucosamine
- n-acetylglucosamine
- n-acetylglucosamine
- n-acetylglucosamine
- n-acetylglucosamine
- n-acetylglucosamine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07225998 | Phase 2 | Feb 1, 2026 | Johns Hopkins University |
| NCT05402345 | Phase 1 | May 31, 2023 | Mayo Clinic |
| NCT04706416 | Phase 1 | Nov 14, 2020 | Quantinosis.ai LLC |
| NCT03716115 | Phase 2 | Jan 31, 2019 | Parirenyatwa Hospital, University of London, University Teaching Hospital, Lusaka, Zambia |
| NCT02511041 | Phase 1 | Jun 30, 2015 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02504060 | Phase 3 | Jun 1, 2015 | People's Liberation Army of China |
| NCT01893606 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2013 | People's Liberation Army of China |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| People's Liberation Army of China | Government | 2 | 2 | 1 | 2013 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2026 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2023 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2015 |
| Parirenyatwa Hospital | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Quantinosis.ai LLC | For profit | 1 | 1 | 1 | 2020 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University Teaching Hospital, Lusaka, Zambia | Academic/Hospital | 1 | 0 | 1 | 2019 |
8 organizations
Page 1 / 1